Barclays PLC Ventyx Biosciences, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 80,295 shares of VTYX stock, worth $182,269. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,295

Previous 80,295 -0.0%

Holding current value

$182,269

Previous $175,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.85 - $3.2 $108,735 - $188,083	58,776 Added 273.14%	80,295 $175,000
Q2 2024 Aug 14, 2024	SELL	$2.31 - $5.59 $26,534 - $64,212	-11,487 Reduced 34.8%	21,519 $51,000
Q1 2024 May 15, 2024	SELL	$1.9 - $10.13 $76,490 - $407,813	-40,258 Reduced 54.95%	33,006 $181,000
Q4 2023 Feb 15, 2024	SELL	$2.08 - $31.18 $322,308 - $4.83 Million	-154,956 Reduced 67.9%	73,264 $181,000
Q3 2023 Nov 07, 2023	BUY	$29.8 - $40.3 $6.1 Million - $8.25 Million	204,762 Added 872.89%	228,220 $7.93 Million
Q2 2023 Aug 03, 2023	BUY	$28.53 - $39.55 $169,867 - $235,480	5,954 Added 34.02%	23,458 $769,000
Q1 2023 May 04, 2023	BUY	$29.51 - $46.65 $196,802 - $311,108	6,669 Added 61.55%	17,504 $586,000
Q4 2022 Feb 13, 2023	BUY	$24.16 - $36.38 $188,133 - $283,291	7,787 Added 255.48%	10,835 $355,000
Q3 2022 Nov 03, 2022	SELL	$12.64 - $38.7 $3.48 Million - $10.7 Million	-275,335 Reduced 98.91%	3,048 $106,000
Q2 2022 Aug 12, 2022	SELL	$11.95 - $18.75 $127,351 - $199,818	-10,657 Reduced 3.69%	278,383 $3.41 Million
Q1 2022 May 16, 2022	BUY	$10.0 - $19.98 $2.89 Million - $5.78 Million	289,040 New	289,040 $3.92 Million

Others Institutions Holding VTYX

# of Institutions

125

Shares Held

52.9M

Call Options Held

35.3K

Put Options Held

83K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account